Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties, including statements regarding the proposed public offering. Various factors may cause differences between TESARO's expectations and actual results, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. More information about potential factors that could affect TESARO's business and financial results is contained in its annual report on Form 10-K, its quarterly reports on Form 10-Q and other filings with the SEC. TESARO does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.About TESAROTESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer.
Investor/Media ContactJennifer DavisSr. Director, Corporate Development & Investor Relations+1.781.325.1116 or firstname.lastname@example.org